Summary
Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk (RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53 mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to 23.4 with a combined RH estimate of 2.0 (confidence interval 1.7–2.5). Three studies investigated the role of p53 in node-negative patients and in these, the combined estimate of RH was 1.7 (1.2–2.3). For three studies of node-positive breast cancer the combined risk estimate was 2.6 (1.7–3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results. Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A. & Lonning, P. E. (1996). Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814.
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K. & McGuire, W. L. (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206.
Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L. & Borresen, A. L. (1993). Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540–548.
Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A. & Millis, R. R. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469–476.
Beck, T., Weller, E. E., Weikel, W., Brumm, C., Wilkens, C. & Knapstein, P. G. (1995). Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynaecol Oncol 57: 96–104.
Bergh, J., Norberg, T., Sjogren, S., Lindgren, A. & Holmberg, L. (1995). Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029–1034.
Berns, E. M., van Staveren, I. L., Look, M. P., Smid, M., Klijn, J. G. & Foekens, J. A. (1998). Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77: 1130–1136.
Bianchi, S., Calzolari, A., Vezzosi, V., Zampi, G., Cardona, G., Cataliotti, L., Bonardi, R. & Ciatto, S. (1997). Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori 83: 669–672.
Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thorlacius, S., Borg, A., Johansson, U., Theillet, C., Scherneck, S., Hartman, S. I., Cornelisse, C. J., Hovig, E. & Devilee, P. (1995). TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chrom. Cancer 14: 71–75.
Breslow, N. E. & Day, N. E. (1980). Statistical Methods in Cancer Research, Vol. 1 The Analysis of Case-Control Studies. International Agency for Research on Cancer: Lyon
Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, W. D. & Parl, F. F. (1994). p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 73: 2147–2156.
Egger, M. & Smith, G. D. (1995). Misleading meta-analysis. Br Med J 310: 752–754.
Elledge, R. M., Fuqua, S. A., Clark, G. M., Pujol, P., Allred, D. C. & McGuire, W. L. (1993). Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26: 225–235.
Elledge, R. M., Clark, G. M., Fuqua, S. A., Yu, Y. Y. & Allred, D. C. (1994). p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752–3757.
Falette, N., Paperin, M. P., Treilleux, I., Gratadour, A. C., Peloux, N., Mignotte, H., Tooke, N., Lofman, E., Inganas, M., Bremond, A., Ozturk, M. & Puisieux, A. (1998). Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 58: 1451–1455.
Gohring, U. J., Scharl, A., Heckel, C., Ahr, A. & Crombach, G. (1995). P53 protein in 204 patients with primary breast carcinoma—immunohistochemical detection and clinical value as a prognostic factor. Arch Gynaecol Obstet 256: 139–146.
Gretarsdottir, S., Tryggvadottir, L., Jonasson, J. G., Sigurdsson, H., Olafsdottir, K., Agnarsson, B. A., Ogmundsdottir, H. & Eyfjord, J. E. (1996). TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 74: 555–561.
Hartmann, A., Blaszyk, H., Kovach, J. S. & Sommer, S. S. (1997). The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13: 27–33.
Iacopetta, B., Grieu, F., Powell, B., Soong, R., McCaul, K. & Seshadri, R. (1998). Analysis of p53 gene mutation by polymerase chain reaction – single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4: 1597–1602.
International Agency for Research into Cancer (1998). The IARC database of somatic p53 mutations in human tumors and cell lines. http://www.iarc.fr/p53/homepage.htm
Isola, J., Visakorpi, T., Holli, K. & Kallioniemi, O. P. (1992). Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114.
Jansson, T., Inganas, M., Sjogren, S., Norberg, T., Lindgren, A., Holmberg, L. & Bergh, J. (1995). p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13: 2745–2751.
Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D. & Sommer, S. S. (1996). Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093–1096.
Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358: 15–16.
Levesque, M. A., Katsaros, D., Yu, H., Giai, M., Genta, F., Roagna, R., Ponzone, R., Massobrio, M., Sismondi, P. & Diamandis, E. P. (1998). Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. Int J Cancer 79: 147–152.
Lipponen, P., Ji, H., Aaltomaa, S., Syrjanen, S. & Syrjanen, K. (1993). p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51–56.
Norberg, T., Lennerstrand, J., Inganas, M. & Bergh, J. (1998). Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 79: 376–383.
Riou, G., Le, M. G., Travagli, J. P., Levine, A. J. & Moll, U. M. (1993). Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85: 1765–1767.
Seshadri, R., Leong, A. S., McCaul, K., Firgaira, F. A., Setlur, V. & Horsfall, D. J. (1996). Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69: 135–141.
Shiao, Y. H., Chen, V. W., Scheer, W. D., Wu, X. C. & Correa, P. (1995). Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55: 1485–1490.
Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G. & Veronesi, U. (1993). p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965–970.
Soong, R., Iacopetta, B. J., Harvey, J. M., Sterrett, G. F., Dawkins, H. J., Hahnel, R. & Robbins, P. D. (1997). Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642–647.
Stenmark-Askmalm, M., Stal, O., Sullivan, S., Ferraud, L., Sun, X. F., Carstensen, J. & Nordenskjold, B. (1994). Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 30A: 175–180.
Thor, A. D., Moore, DHII, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H. & Smith, H. S. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845–855.
Thorlacius, S., Thorgilsson, B., Bjornsson, J., Tryggvadottir, L., Borresen, A. L., Ogmundsdottir, H. M. & Eyfjord, J. E. (1995). TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A: 1856–1861.
Tsuda, H., Sakamaki, C., Tsugane, S., Fukutomi, T. & Hirohashi, S. (1998). A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48: 21–32.
Valgardsdottir, R., Tryggvadottir, L., Steinarsdottir, M., Olafsdottir, K., Jonasdottir, S., Jonasson, J. G., Ogmundsdottir, H. M. & Eyfjord, J. E. (1997). Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105: 121–130.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pharoah, P., Day, N. & Caldas, C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80, 1968–1973 (1999). https://doi.org/10.1038/sj.bjc.6690628
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690628
Keywords
This article is cited by
-
Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood–brain barrier and treatment strategies
Clinical and Translational Oncology (2023)
-
Histone Modifying Potential of Dietary Phytochemicals: Implications in Treating Breast Cancer
Current Pharmacology Reports (2023)
-
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer
Breast Cancer Research and Treatment (2020)
-
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations
BMC Medical Genomics (2019)
-
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer
Breast Cancer Research (2016)